The European Medicines Agency said today that it was investigating cases of atypical blood clots in women who had been vaccinated with Johnson & Johnson’s coronavirus, Reuters reported.
In a statement, EAL said it was unclear whether there was a link between the vaccine and the rare health condition. The agency will announce its position once it has completed its assessment.
At the same time, the EC sought clarification from Johnson & Johnson regarding the company’s completely unexpected announcement of delays in the supply of its vaccine to the EU, Reuters reported, citing an unnamed representative.
The US company announced earlier today that it will delay the spread of its vaccine in Europe after the US federal health authorities recommended a temporary suspension of the drug after cases of rare blood clots in 6 women under 50 vaccinated with the product.
–
